|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����ҩ |
|
�����Ҿ� |
|
ҩ��,�ٴ����� |
| ��������������� | |
|
�»� |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
���Ϳ����ҩ�￨���Ҿ��������ٴ���Ӧ��
�»�, ��ά��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
�����Ҿ�����������ʳƷ��ҩƷ������������ٴ��ļ������B��ҩ��,��һ�֦�-(1,3)-�Ͼ��Ǻϳ�ø�ķǾ��������Ƽ�,��Ӱ�����ϸ���ڵĺϳ�,�Ӷ����п�����Ļ��ԡ����������Ҿ������û��Ƽ��ٴ�Ӧ�á�
[2] Denning DW. Echinocandin antifungal drugs. Lancet, 2003, 362:1142-1151.
[3] Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos, 2000, 28:1274-1278.
[4] Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother, 2003, 47:1068-1071.
[5] Ju JY, Polhamus C, Marr KA, et al. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/knockout mice. Antimicrob Agents Chemother, 2002, 46:1240-1245.
[6] Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin,itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 2003, 41:3623-3626.
[7] Kirkpatrick WR, Perea S, Coco B J, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother, 2002, 46:2564-2568.
[8] Powles MA, Liberator P, Anderson J,et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother, 1998, 42:1985-1989.
[9] Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol, 1998, 36:2950-2956.
[10] Kohler S, Wheat LJ, Connolly P,et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother, 2000, 44:1850-1854.
[11] van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother, 2002, 46:3394-3400.
[12] Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother, 1997, 41:1957-1960.
[13] Villanueva A, Arathoon EG, Gotuzzo E,et al. A randomized doubleblind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis, 2001,33:1529-1535.
[14] Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, doubleblind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother, 2002, 46:451-457.
[15] Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis:results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis, 2003, 22:470-474.
[16] Garbino J, Lew D, Hirschel B, et al. Caspofungin in the treatment of oropharyngeal candidiasis. Int J Clin Pract, 2003, 57:143-144.
[17] Elanjikal Z, Sorensen J, Schmidt H, et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis.Pediatr Infect Dis J, 2003, 22:653-656.
[18] Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia:successful therapy with combination caspofungin and liposomal amphotericin. Cancer, 2003, 97:1025-1032.
[19] Trinh JV, Steinbach WJ, Schell WA, et al. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol, 2003, 41:339-345.
[20] Voitl P, Scheibenpflug C, Weber T, et al. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis, 2002, 21:632-634.
[21] Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus:rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis, 2002, 34:1415-1417.